The treatment, named AZD7442, is a combination tixagevimab and cilgavimab.
At primary analysis, none of the trial participants who contracted symptomatic COVID-19 had severe cases. More than 75 percent of participants had comorbidities, including conditions that cause a reduced immune response to vaccination.
“We need additional approaches for individuals who are not adequately protected by COVID-19 vaccines,” Sir Mene Pangalos, PhD, AstraZeneca’s executive vice president of biopharmaceuticals and research and development, said in a news release. “We are very encouraged by these efficacy and safety data in high-risk people, showing our long-acting antibody combination has the potential to protect from symptomatic and severe disease, alongside vaccines.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
